"Immunotherapy, Adoptive" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314)
| Descriptor ID |
D016219
|
| MeSH Number(s) |
E02.095.465.425.400.330.050.400 E05.478.550.520.050.400
|
| Concept/Terms |
Immunotherapy, Adoptive- Immunotherapy, Adoptive
- Immunotherapy, Adoptive Cellular
- Adoptive Immunotherapy
- Adoptive Immunotherapies
- Immunotherapies, Adoptive
- Cellular Immunotherapy, Adoptive
- Adoptive Cellular Immunotherapies
- Cellular Immunotherapies, Adoptive
- Immunotherapies, Adoptive Cellular
- Adoptive Cellular Immunotherapy
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Adoptive".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Adoptive".
This graph shows the total number of publications written about "Immunotherapy, Adoptive" by people in this website by year, and whether "Immunotherapy, Adoptive" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 3 | 3 |
| 2003 | 2 | 4 | 6 |
| 2004 | 2 | 4 | 6 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 2 | 3 |
| 2010 | 4 | 2 | 6 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 2 | 5 |
| 2013 | 5 | 0 | 5 |
| 2014 | 3 | 1 | 4 |
| 2015 | 4 | 2 | 6 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 6 | 1 | 7 |
| 2019 | 6 | 2 | 8 |
| 2020 | 5 | 1 | 6 |
| 2021 | 15 | 2 | 17 |
| 2022 | 2 | 13 | 15 |
| 2023 | 2 | 11 | 13 |
| 2024 | 15 | 7 | 22 |
| 2025 | 16 | 5 | 21 |
| 2026 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Adoptive" by people in Profiles.
-
Ibrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma. Blood Adv. 2026 Feb 24; 10(4):1023-1034.
-
Tuning CAR-T cells by targeting cancer-associated glycan in pancreatic cancer. Nat Commun. 2025 Dec 10; 16(1):11246.
-
In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma. Nature. 2025 Oct; 646(8086):953-962.
-
Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency. Cancer Immunol Res. 2025 Aug 01; 13(8):1132-1144.
-
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy. Blood Adv. 2025 Jun 10; 9(11):2763-2772.
-
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. Blood. 2025 Jun 05; 145(23):2762-2767.
-
IFN-?-resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models. Sci Transl Med. 2025 Jun 04; 17(801):eadp8166.
-
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response. Blood. 2025 May 22; 145(21):2460-2472.
-
Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study. Blood. 2025 May 15; 145(20):2303-2311.
-
Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma. Nat Commun. 2025 May 06; 16(1):4205.